Natanel Barookhian: NavDx aids in the detection of HPV-driven cancers with unparalleled accuracy and specificity
Natanel Barookhian, Founder of
“Naveris first earned our attention and investment in 2019, amidst the development of their pioneering liquid biopsy test, NavDx. As the first and only blood test of its kind to be clinically validated, NavDx aids in the detection of HPV-driven cancers with unparalleled accuracy and specificity.
Recently, the company celebrated a significant achievement: receiving the Advanced Diagnostic Laboratory Test (ADLT) designation from the Centers for Medicare and Medicaid Services. This prestigious recognition marks a major milestone toward achieving the broad accessibility required for saving lives at scale.
Congratulations to Piyush Gupta, James McNally, and the entire Naveris Inc team. We are proud of the impact you are making on the world.”
Source: Natanel Barookhian/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023